Complementing these findings, LRRK2-mediated centrosomal cohesion deficits in peripheral lymphoblastoid cells from G2019S LRRK2-PD patients, reversible by LRRK2 inhibitors, propose a novel cellular biomarker for patient stratification in LRRK2-targeted therapies [59]. The gene discussed is LRRK2; the disease is Parkinson disease.